GSK PLC Statement: Zantac (ranitidine) litigation (8794I)

TIDMGSK

RNS Number : 8794I

GSK PLC

07 December 2022

Issued: 07 December 2022, London UK

Statement: Zantac (ranitidine) litigation

   --   MDL Court has dismissed all cases alleging the five remaining cancers in the MDL 

-- Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer

-- GSK will continue to defend itself vigorously, including against all claims brought at the state level in the U.S.

In response to yesterday's court ruling in the Zantac federal Multi-District Litigation (MDL) in the U.S., GSK plc (LSE/NYSE: GSK) today issued the following statement:

GSK welcomes yesterday's ruling by the MDL Court. Following the 12 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. Yesterday's ruling reflects the state of that science and ensured that unreliable and litigation-driven science did not enter the federal courtroom.

In excluding plaintiffs' epidemiological evidence and expert testimony based on their deficiencies and unreliability, the Court has dismissed all MDL cases alleging the five remaining cancers in the MDL (liver, bladder, pancreatic, esophageal, and stomach). GSK will continue to defend itself vigorously, including against all claims brought at the state level.

Further information regarding the litigation can be found in GSK's 11 August 2022 and 16 August 2022 statements, and in its third quarter results press release issued on 2 November 2022. These are available on www.gsk.com .

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company

 
GSK enquiries 
Media:               Tim Foley          [phone]      (London) 
                                         5502 
                     Madeleine Breckon  [phone]      (London) 
                                         5502 
                     Kathleen Quinn     [phone]      (Washington DC) 
                     Lyndsay Meyer      [phone]      (Washington DC) 
 
Investor Relations:  Nick Stone         [phone]  (London) 
                     James Dodwell      [phone]      (London) 
                                         2406 
                     Mick Readey        [phone]  (London) 
                     Josh Williams      [phone]  (London) 
                     Jeff McLaughlin    [phone]      (Philadelphia) 
                     Frannie DeFranco   [phone]      (Philadelphia) 
 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q3 Results for 2022 and any impacts of the COVID-19 pandemic.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

STRUPGUWPUPPUQM

(END) Dow Jones Newswires

December 07, 2022 02:00 ET (07:00 GMT)